146 related articles for article (PubMed ID: 2120422)
1. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver.
Tanswell P; Heinzel G; Greischel A; Krause J
J Pharmacol Exp Ther; 1990 Oct; 255(1):318-24. PubMed ID: 2120422
[TBL] [Abstract][Full Text] [Related]
2. Total body and hepatic clearance in rats of recombinant tissue-type plasminogen activator expressed in mouse C127 and Chinese hamster ovary cells.
Hori R; He YL; Shima T; Inui K; Aoki S; Okumura K; Tanigawara Y
Drug Metab Dispos; 1992; 20(4):541-6. PubMed ID: 1356732
[TBL] [Abstract][Full Text] [Related]
3. Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system.
Wing LR; Hawksworth GM; Bennett B; Booth NA
J Lab Clin Med; 1991 Feb; 117(2):109-14. PubMed ID: 1899689
[TBL] [Abstract][Full Text] [Related]
4. Hepatic clearance of tissue-type plasminogen activator in rats.
Emeis JJ; van den Hoogen CM; Jense D
Thromb Haemost; 1985 Oct; 54(3):661-4. PubMed ID: 3937264
[TBL] [Abstract][Full Text] [Related]
5. Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver.
Smedsrød B; Einarsson M
Thromb Haemost; 1990 Feb; 63(1):60-6. PubMed ID: 2160132
[TBL] [Abstract][Full Text] [Related]
6. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator.
de Boer A; Kluft C; Kroon JM; Kasper FJ; Schoemaker HC; Pruis J; Breimer DD; Soons PA; Emeis JJ; Cohen AF
Thromb Haemost; 1992 Jan; 67(1):83-7. PubMed ID: 1615490
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and hepatic catabolism of tissue-type plasminogen activator.
Tanswell P; Seifried E; Stang E; Krause J
Arzneimittelforschung; 1991 Dec; 41(12):1310-9. PubMed ID: 1815534
[TBL] [Abstract][Full Text] [Related]
8. Endocytosis of the recombinant tissue plasminogen activator alteplase by hepatic endothelial cells.
Seydel W; Stang E; Roos N; Krause J
Arzneimittelforschung; 1991 Feb; 41(2):182-6. PubMed ID: 1904231
[TBL] [Abstract][Full Text] [Related]
9. The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats.
van der Kaaden ME; Rijken DC; Kruijt JK; van Berkel TJ; Kuiper J
Thromb Haemost; 1997 Apr; 77(4):710-7. PubMed ID: 9134648
[TBL] [Abstract][Full Text] [Related]
10. An experimental multiple-organ model for the study of regional net release/uptake rates of tissue-type plasminogen activator in the intact pig.
Jern C; Seeman-Lodding H; Biber B; Winsö O; Jern S
Thromb Haemost; 1997 Sep; 78(3):1150-6. PubMed ID: 9308769
[TBL] [Abstract][Full Text] [Related]
11. Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim): species differences among rats, monkeys and humans.
Kuwabara T; Kato Y; Kobayashi S; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 1994 Dec; 271(3):1535-43. PubMed ID: 7527856
[TBL] [Abstract][Full Text] [Related]
12. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator.
van Griensven JM; Huisman LG; Stuurman T; Dooijewaard G; Kroon R; Schoemaker RC; Kluft K; Cohen AF
Clin Pharmacol Ther; 1996 Nov; 60(5):504-11. PubMed ID: 8941023
[TBL] [Abstract][Full Text] [Related]
13. Internalization of recombinant tissue-type plasminogen activator by isolated rat hepatocytes is via coated pits.
Marks GJ; Hart TK; Rush GF; Hoffstein ST; Fong KL; Bugelski PJ
Thromb Haemost; 1990 Apr; 63(2):251-8. PubMed ID: 1973006
[TBL] [Abstract][Full Text] [Related]
14. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the interaction of a complex of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 with rat liver cells.
Kuiper J; Otter M; Voorschuur AH; van Zonneveld AJ; Rijken DC; van Berkel TJ
Thromb Haemost; 1995 Nov; 74(5):1298-304. PubMed ID: 8607113
[TBL] [Abstract][Full Text] [Related]
16. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
17. Cluster mannosides can inhibit mannose receptor-mediated tissue-type plasminogen activator degradation by both rat and human cells.
Noorman F; Barrett-Bergshoeff MM; Biessen EA; van de Bilt E; van Berkel TJ; Rijken DC
Hepatology; 1997 Nov; 26(5):1303-10. PubMed ID: 9362376
[TBL] [Abstract][Full Text] [Related]
18. 39-kD protein inhibits tissue-type plasminogen activator clearance in vivo.
Warshawsky I; Bu G; Schwartz AL
J Clin Invest; 1993 Aug; 92(2):937-44. PubMed ID: 8349826
[TBL] [Abstract][Full Text] [Related]
19. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the fibronectin finger-like domain and the kringle 1 domain.
Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
Thromb Haemost; 1994 Dec; 72(6):893-9. PubMed ID: 7740460
[TBL] [Abstract][Full Text] [Related]
20. Elimination of native and carbohydrate-modified tissue plasminogen activator in rabbits.
Einarsson M; Hggroth L; Mattsson C
Thromb Haemost; 1989 Dec; 62(4):1088-93. PubMed ID: 2515604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
